Compare RKDA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | MBIO |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 4.1M |
| IPO Year | 2015 | 2023 |
| Metric | RKDA | MBIO |
|---|---|---|
| Price | $0.44 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 60.3K | 24.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.92 | ★ 98.99 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,858,000.00 | N/A |
| Revenue This Year | $61.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.47 |
| 52 Week High | $6.71 | $1.84 |
| Indicator | RKDA | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | N/A |
| Support Level | $0.39 | N/A |
| Resistance Level | $0.55 | N/A |
| Average True Range (ATR) | 0.04 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 28.56 | 0.00 |
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.